ac295603-d08a-43f7-a78b-610be32aa49f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.400
- UV_RESPONSE_DN+0.300
- ALLOGRAFT_REJECTION+0.200
- ANDROGEN_RESPONSE+0.200
- SPERMATOGENESIS+0.200
- BILE_ACID_METABOLISM+0.100
- COMPLEMENT+0.100
- INTERFERON_GAMMA_RESPONSE+0.100
- KRAS_SIGNALING_UP+0.100
- MYC_TARGETS_V1+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- APICAL_JUNCTION-0.300
- ANGIOGENESIS-0.200
- CHOLESTEROL_HOMEOSTASIS-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- ESTROGEN_RESPONSE_LATE-0.200
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-7727-01A-11R-2170-07 | — | cohortMD2 | 0.821 |
| 2 | MNG636 | — | — | 0.790 |
| 3 | TCGA-44-3918-01A-01R-A278-07 | — | cohortMD2 | 0.768 |
| 4 | MNG724 | — | — | 0.750 |
| 5 | SRR2016949 | — | — | 0.748 |
| 6 | b9389390-aa03-406c-957e-2bc264f9468e | — | — | 0.735 |
| 7 | R82 | — | — | 0.733 |
| 8 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.732 |
| 9 | TCGA-44-2656-01A-02R-A278-07 | — | cohortMD2 | 0.722 |
| 10 | SRR12475117 | — | — | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |